# A Study of Liposomal Trans Crocetin, LEAF-4L6715, in Patients With Acute Respiratory Distress Syndrome Due to COVID-19, Sepsis or Other Causes

> **NCT04378920** · PHASE1,PHASE2 · COMPLETED · sponsor: **Institut de cancérologie Strasbourg Europe** · enrollment: 37 (actual)

## Conditions studied

- COVID19, Sepsis or Other Causes
- Acute Respiratory Distress Syndrome

## Interventions

- **DRUG:** LEAF-4L6715

## Key facts

- **NCT ID:** NCT04378920
- **Lead sponsor:** Institut de cancérologie Strasbourg Europe
- **Sponsor class:** OTHER
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2020-04-14
- **Primary completion:** 2021-08-24
- **Final completion:** 2021-08-24
- **Target enrollment:** 37 (ACTUAL)
- **Last updated:** 2021-12-16

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04378920

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04378920, "A Study of Liposomal Trans Crocetin, LEAF-4L6715, in Patients With Acute Respiratory Distress Syndrome Due to COVID-19, Sepsis or Other Causes". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT04378920. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*